|
Relationship between quality of life (QoL) and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients after chemotherapy: Results from the AFFIRM study. |
|
|
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Janssen-Cilag; Medivation; Novartis; Roche/Genentech |
Speakers' Bureau - Bayer; Janssen-Cilag; Novartis |
|
|
Stock and Other Ownership Interests - FACIT.org |
Consulting or Advisory Role - Abbvie; Bayer; GlaxoSmithKline; Pfizer |
Research Funding - Bayer (Inst); Genentech (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Bayer; GlaxoSmithKline |
|
|
Employment - Astellas Pharma; Astellas Pharma |
|
|
Employment - Astellas Pharma |
|
|
Employment - Astellas Pharma |
|
|
|
Consulting or Advisory Role - Astellas Pharma (Inst) |
|
|
No Relationships to Disclose |